NAFLD (non-alcoholic fatty liver disease) represents a spectrum of fatty liver diseases associated with an increased risk of Type 2 diabetes and cardiovascular disease. The spectrum of fatty liver diseases comprises simple steatosis, steatosis with inflammation [i.e. NASH (non-alcoholic steatohepatitis)], fatty liver disease with inflammation and fibrosis (severe NASH) and cirrhosis. The molecular mechanisms contributing to NASH are the subject of considerable investigation, as a better understanding of the pathogenesis of NASH will lead to novel therapies for a condition that hitherto remains difficult to treat. In the present issue of Clinical Science, Piguet and co-workers have investigated the effects of hypoxia in the PTEN (phosphatase and tensin homologue deleted on chromosome 10)-deficient mouse, a mouse model that develops NAFLD. The authors show that a short period (7 days) of exposure to hypoxia aggravates the NAFLD phenotype, causing changes in the liver that are in keeping with NASH with increased lipogenesis and inflammation.
Skip Nav Destination
Commentary| December 14 2009
Hypoxia and non-alcoholic fatty liver disease
Christopher D. Byrne
1Department of Endocrinology and Metabolism, The Institute of Developmental Sciences, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, U.K.
Correspondence: Professor Christopher D. Byrne (email email@example.com).
Search for other works by this author on:
Clin Sci (Lond) (2010) 118 (6): 397–400.
November 04 2009
November 10 2009
Accepted Manuscript online:
November 10 2009
Christopher D. Byrne; Hypoxia and non-alcoholic fatty liver disease. Clin Sci (Lond) 1 March 2010; 118 (6): 397–400. doi: https://doi.org/10.1042/CS20090565
Download citation file:
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your InstitutionSign in via your Institution
Get Access To This Article
Buy This Article